Physician profile
Charles J Eldredge
NPI 1215989322
$1,202.16
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.98 · 2020: $13.76 · 2021: $211 · 2022: $184 · 2023: $197 · 2024: $340 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.09 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $174.00 | 2021 | |
| Nxstage Medical, INC. | $172.78 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Amgen INC. | $160.64 | 2019-2024 | Aranesp, Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $147.13 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.52 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $74.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $66.33 | 2020-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $58.69 | 2024-2025 | |
| Glaxosmithkline, LLC. | $55.75 | 2022-2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $49.22 | 2024 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.06 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $35.14 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $33.74 | 2021-2022 | |
| Scpharmaceuticals INC. | $17.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Eldredge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.